Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Cancer Drug Targets

• Publication date

  2008-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/156800908784293604PMID 18473736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccines for tumour prevention

  2006cited by this paper
• A novel dendritic cell subset involved in tumor immunosurveillance

  2006cited by this paper
• Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.

  2006cited by this paper
• Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.

  2006cited by this paper
• Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice1

  2006cited by this paper
• CpG-Containing Oligodeoxynucleotides Act through TLR9 to Enhance the NK Cell Cytokine Response to Antibody-Coated Tumor Cells 1

  2005cited by this paper
• Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

  2005cited by this paper
• The promise of genetically engineered mice for cancer prevention studies

  2005cited by this paper
• The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice.

  2005cited by this paper
• Trastuzumab in the treatment of breast cancer.

  2005cited by this paper
• Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration.

  2005cited by this paper
• Natural Killer Dendritic Cells Have Both Antigen Presenting and Lytic Function and in Response to CpG Produce IFN-γ via Autocrine IL-121

  2005cited by this paper
• A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.

  2005cited by this paper
• Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.

  2004cited by this paper
• Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

  2004cited by this paper
• Immunostimulatory Effects of CpG-ODN Upon Dendritic Cell-Based Immunotherapy in a Murine Melanoma Model

  2004cited by this paper
• Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice

  2004cited by this paper
• Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

  2004cited by this paper
• Immunobiology of Her-2/Neu Transgenic Mice

  2004cited by this paper
• Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

  2003cited by this paper
• CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.

  2003cited by this paper
• CpG motifs: the active ingredient in bacterial extracts?

  2003cited by this paper
• Vaccination with Tumor Peptide in CpG Adjuvant Protects Via IFN-γ-Dependent CD4 Cell Immunity1

  2002cited by this paper
• Combined dendritic cell‐ and CpG oligonucleotide‐based immune therapy cures large murine tumors that resist chemotherapy

  2002cited by this paper
• Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model1

  2002cited by this paper
• Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.

  2002cited by this paper
• Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.

  2002cited by this paper
• Prevention of spontaneous mammary adenocarcinoma in HER‐2/neu transgenic mice by foreign DNA

  2002cited by this paper
• A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia.

  2001cited by this paper
• CpG DNA induces cyclooxygenase-2 expression and prostaglandin production.

  2001cited by this paper
• Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice

  2001cited by this paper
• Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo1

  2000cited by this paper
• A Toll-like receptor recognizes bacterial DNA

  2000cited by this paper
• CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.

  1999cited by this paper
• Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis.

  1999cited by this paper
• Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

  1998cited by this paper
• Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness.

  1998cited by this paper
• Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice

  1998cited by this paper
• Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.

  1998cited by this paper
• CD4+, but not CD8+, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-gamma: role of phosphatidyl serine.

  1998cited by this paper
• CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity

  1997cited by this paper
• Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.

  1997cited by this paper
• The discovery and function of COX-2.

  1997cited by this paper
• Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo

  1996cited by this paper
• Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.

  1996cited by this paper
• Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.

  1996cited by this paper
• Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease.

  1994cited by this paper
• Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines.

  1991cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The macrophage as the social interconnection within the immune system.

  1980cited by this paper

• Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

  2014cites this paper
• ANTI-TUMOR ACTIVITY OF CPG-ODN IN OVARIAN XENOGRAFT TUMORS

  2014cites this paper
• Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

  2013cites this paper
• Increased Numbers of Monocyte-Derived Dendritic Cells during Successful Tumor Immunotherapy with Immune-Activating Agents

  2013cites this paper
• AgentsImmunotherapy with Immune-Activating Dendritic Cells during Successful Tumor Increased Numbers of Monocyte-Derived

  2013cites this paper
• CpG Oligodeoxynucleotides as TLR9 Agonists

  2012cites this paper
• BALB-neuT Female Mice as a Dynamic Model of Mammary Cancer

  2012cites this paper
• Liposome-anchored local delivery of immunomodulatory agents for tumor therapy

  2012cites this paper
• Using Natural Adjuvants to Stimulate Anti-Tumour Immune Responses

  2012cites this paper
• Engineering Nano‐ and Microparticles to Tune Immunity

  2012cites this paper
• Vaccines and other immunological approaches for cancer immunoprevention.

  2011cites this paper
• HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy

  2011cites this paper
• Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans

  2011cites this paper
• A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions

  2011cites this paper
• Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice

  2010cites this paper
• A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.

  2010cites this paper
• Vaccination against Her2/neu - expressing cancer using chimeric virus-like particles

  2009cites this paper
• Targeted Liposomal Delivery of TLR9 Ligands Activates Spontaneous Antitumor Immunity in an Autochthonous Cancer Model1

  2009cites this paper
• Model Immunity in an Autochthonous Cancer Ligands Activates Spontaneous Antitumor Targeted Liposomal Delivery of TLR 9

  2009cites this paper
• An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

  2009cites this paper
• Murine pneumotropic virus chimeric Her2/neu virus‐like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors

  2009cites this paper